Tremelimumab

Adjuvant durvalumab significantly improved PFS and OS compared with placebo among patients with limited-stage small cell lung cancer, according to study results presented at ESMO Congress.

The FDA approved the use of durvalumab in combination with carboplatin and paclitaxel followed by single-agent durvalumab for women with mismatch repair-deficient primary advanced or recurrent endometrial cancer.

The combination of durvalumab and tremelimumab-actl conferred a sustained OS benefit at 4 years among patients with unresectable hepatocellular carcinoma, according to phase 3 trial results from the agents’ manufacturer.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

The FDA approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for certain patients with metastatic non-small cell lung cancer.

The FDA approved tremelimumab in combination with durvalumab for adults with unresectable hepatocellular carcinoma.

Durvalumab plus tremelimumab significantly extended OS compared with sorafenib among patients with advanced, unresectable hepatocellular carcinoma, according to research scheduled for presentation at ASCO Gastrointestinal Cancers Symposium.

The addition of tremelimumab to first-line durvalumab significantly improved OS compared with sorafenib for certain patients with unresectable hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.

In this video, Upal Basu Roy, PhD, MPH, spoke with Healio about “fantastic presentations” from this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer.

First-line treatment with durvalumab plus tremelimumab and chemotherapy appeared effective for patients with metastatic non-small cell lung cancer, according to randomized phase 3 study results.